Details of the Drug Pharmacogenomic Perturbation Atlas

Darifenacin Drug Info

Enablex; Emselex; 133099-04-4; UNII-APG9819VLM; UK-88525; APG9819VLM; CHEMBL1346; CHEBI:391960; (S)-1-(2-(2,3-Dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide; 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide; darifenacine; [3H]darifenacin; 2-{(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-diphenylacetamide; NCGC00168775-01; Darifenacin (USAN/INN); Darifenacinum; Darifenacina; Darifenacin [USAN:INN:BAN]; Emselex; Emselex (TN); Enablex (TN)

Therapeutic Class

Urinary antispasmodics

Cross-matching ID

PubChem CID

444031

ChEBI ID

CHEMBL1346

CAS Number

CAS 133099-04-4

TTD Drug ID

D0Y5AM

INTEDE Drug ID

DR0417

ACDINA Drug ID

D00169

General Information of Drug (ID: DMWXLYZ)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Drug metabolism	2.31	0.00e+0	78/151 (51.66%)	GSTP1;UGT2B15;UGT2B28;...
Retinol metabolism	2.27	0.00e+0	41/68 (60.29%)	UGT2B15;UGT2B28;UGT2B17;...
Pentose and glucuronate interconversions	2.22	0.00e+0	17/34 (50%)	UGT2B15;AKR1A1;UGT2B28;...
Pyruvate metabolism	2.11	0.00e+0	41/47 (87.23%)	AKR1A1;DLD;PCK1;...
Glycolysis / Gluconeogenesis	2.00	0.00e+0	56/67 (83.58%)	PFKL;AKR1A1;DLD;...
Tyrosine metabolism	1.99	1.55e-3	30/36 (83.33%)	ADH1C;GOT1;ADH5;...
Steroid hormone biosynthesis	1.98	1.33e-3	43/61 (70.49%)	UGT2B15;UGT2B28;UGT2B17;...
Ascorbate and aldarate metabolism	1.97	1.16e-3	15/30 (50%)	UGT2B15;AKR1A1;UGT2B28;...
Metabolism of xenobiotics by cytochrome P450	1.97	1.03e-3	49/77 (63.64%)	GSTP1;UGT2B15;UGT2B28;...
Asthma	1.97	9.30e-4	25/31 (80.65%)	HLA-DPB1;HLA-DPA1;CD40;...
Pentose phosphate pathway	1.91	4.23e-3	25/30 (83.33%)	PFKL;DERA;ALDOB;...
Porphyrin and chlorophyll metabolism	1.86	6.97e-3	23/43 (53.49%)	UGT2B15;UGT2B28;UGT2B17;...
Fatty acid degradation	1.86	6.44e-3	40/43 (93.02%)	ACAT2;ADH1C;ACAA2;...
Tryptophan metabolism	1.84	5.98e-3	35/42 (83.33%)	AOC1;DLD;ACAT2;...
Peroxisome	1.84	5.58e-3	72/82 (87.8%)	EPHX2;ACOX2;PIPOX;...
Valine, leucine and isoleucine degradation	1.80	5.81e-3	42/48 (87.5%)	DLD;HMGCS2;ACAT2;...
Propanoate metabolism	1.79	7.11e-3	30/34 (88.24%)	DLD;ACAT2;EHHADH;...
Primary bile acid biosynthesis	1.77	8.26e-3	15/17 (88.24%)	SLC27A5;ACOX2;CYP27A1;...
Starch and sucrose metabolism	1.76	1.08e-2	25/36 (69.44%)	MGAM;UGP2;GBE1;...
Steroid biosynthesis	1.75	1.12e-2	19/20 (95%)	MSMO1;LSS;CYP51A1;...
Arginine and proline metabolism	1.74	1.37e-2	39/50 (78%)	OAT;AOC1;LAP3;...
Intestinal immune network for IgA production	1.74	1.44e-2	38/48 (79.17%)	HLA-DPB1;CXCL12;HLA-DPA1;...
Butanoate metabolism	1.72	1.46e-2	23/28 (82.14%)	HMGCS2;ACAT2;HMGCL;...
Systemic lupus erythematosus	1.71	1.74e-2	45/135 (33.33%)	HLA-DPB1;ACTN1;HLA-DPA1;...
Oxidative phosphorylation	1.70	2.08e-2	93/133 (69.92%)	COX6B1;NDUFA3;ATP5MC2;...
Glycerolipid metabolism	1.70	2.04e-2	44/61 (72.13%)	LPIN1;AKR1A1;MGLL;...
Bile secretion	1.67	2.65e-2	68/90 (75.56%)	CA2;UGT2B15;UGT2B28;...
Allograft rejection	1.67	2.56e-2	32/38 (84.21%)	HLA-DPB1;HLA-DPA1;CD40;...
Glutathione metabolism	1.65	2.95e-2	43/57 (75.44%)	GPX3;GSTP1;LAP3;...
Lysine degradation	1.64	3.22e-2	51/63 (80.95%)	DLD;ACAT2;PIPOX;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H

MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	24H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	24H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	24H